THUNDERCOMM
15.3.2023 04:57:35 CET | Business Wire | Press release
Thundercomm, a world leading IoT product and solution provider, announces the release of new offerings in its smart IoT module portfolio to lower the barriers to enter the market and accelerate innovation in various AIoT industry segments, including robotics, handheld devices, tablets and smart cameras.
TurboX C2210 SOM is powered by the Qualcomm® QRB2210 System-on-Chip (SoC). It's designed with an optimized Linux operating system, discrete memory for more memory options to save the cost, and system fast boot, supports 1080P@30FPS video decode and a long life cycle to 2028, aiming to bring advanced features to entry-level devices with better performance and improved power consumption. The TurboX C2210 SOM supports the Linux system and can be applied to a variety of products like entry-tier robotics, e-scooter, smart home dock, smart camera and rugged handheld, etc.
TurboX C4210 SOM is powered by the Qualcomm® QRB4210 SoC. It features triple ISPs for advanced dual-camera experience, dedicated Compute DSP for computer vision and video post-processing. It's designed to support advanced graphics, bringing high value features to mid-tier devices. It's an ideal platform for both industrial and consumer applications requiring high data rates multimedia function, and can be applied to a broad range of devices including robotics, dash camera, video conference, smart retail, etc.
TurboX C5430 SOM integrates the Qualcomm® QCS5430 SoC, a 6nm processor with superior performance, power efficiency, premium connectivity, and 3.5 TOPS computing power. It supports 4K@30FPS video decode and 4K@30FPS video encode, Wi-Fi 6E, long range bluetooth, four MIPI CSIs, as well as a rich set of peripheral interfaces. The C5430 SOM is a high performance AIoT SOM for building handheld devices, industrial robots, service robots, Edge Box, providing customers with hardware interfaces and software SDK to validate functions and build the prototype quickly.
“Robotics industry is growing faster than ever as technology continuously advances in 5G, computing power and AI. Today, we see robots in almost every aspect of our lives, helping us do much more than we can do alone. Our newly released C2210 SOM and C4210 SOM will unlock the potential of more innovations in robotics, lowering the barriers for brands to enter and compete efficiently in this growing market,” said Pier Zhang, Director of Product Marketing at Thundercomm. “We are offering not only the hardware SOM and dev kits, but also the robot brain, software solutions to help customers build future-proof robot products faster and cost-effectively.”
“We congratulate Thundercomm on the launch of their industry leading SOMs. Recognizing the innovation of these new products, Qualcomm Technologies recently announced Qualcomm® Robotics RB1 and RB2 Development Kits are based on TurboX C2210 and C4210 respectively,” said Dev Singh, vice president, business development, and head of building, enterprise and industrial automation, Qualcomm Technologies, Inc. “Boosting a suite of complete robotics capabilities, including pre-integrated sensors from TDK, cameras, and AI SDKs, our development kits will enable developers to more easily prototype everyday robotics applications thus helping push the IoT ecosystem forward.”
The Qualcomm Robotics RB1 and RB2 Development Kit and SOMs of TurboX C2210, C4210, C5430 are available now for evaluation and testing.
About Thundercomm
Thundercomm, a joint venture between Thunder Software Technology Co., Ltd and Qualcomm (China) Holding Co. Ltd., a subsidiary of Qualcomm Technologies, Inc., was established to accelerate innovation in the Internet of Things and automotive industry, providing one-stop solutions powered by Qualcomm Technologies. Through its capabilities in operating systems including Android, Linux, and others, abroad software and on-device AI technology portfolio, and a global sales and support network, Thundercomm is a valuable and trusted partner to global customers aiming to build high-quality, next-generation products and shorten time-to-commercialization. Learn more at www.thundercomm.com
Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314006083/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom